View Older Stories
-
Abbvie (ABBV) PT Raised to $153 at BMO Capital Following Bullish Update
-
Abbvie (ABBV) PT Raised to $134 at BMO Capital
-
Abbvie (ABBV) PT Raised to $129 at BMO Capital
-
BMO Capital Starts Abbvie (ABBV) at Outperform; Well-Positioned to Manage Humira's LOE
-
UPDATE: BMO Capital Upgrades Abbvie (ABBV) to Market Perform
-
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
-
AbbVie sees hit to Humira sales from European competition
-
Abbvie (ABBV) CA Suit 'Incrementally Negative' - BMO
-
Olumiant 2mg FDA Approval is Incrementally Negative for AbbVie (ABBV) - BMO
-
Abbvie (ABBV) PT Lowered to $78 at BMO Capital
-
Abbvie (ABBV) PT Raised to $81 at BMO Capital
-
Bari Adcom Negative for Eli Lilly (LLY) and AbbVie (ABBV), Positive for Pfizer (PFE) - BMO
-
AbbVie (ABBV) Has Downside as Underappreciated Risks are Materializing - BMO Capital
-
AbbVie (ABBV), Eli Lilly (LLY) More Vulnerable Than Other Drug Cos. on Amazon Entry - BMO
-
BMO Capital Downgrades Abbvie (ABBV) to Underperform; 'Risk/Reward Skewed to the Downside'
-
AbbVie (ABBV): The Upside To IPR Loss - BMO
-
Abbvie (ABBV) PT Raised to $66 at BMO Capital; 'Should Finish 2017 at Top-End of Guidance'
-
AbbVie (ABBV): Pipeline Confidence Weakening - BMO
-
AbbVie (ABBV): Still Concerned About Long Term - BMO
-
Complete Donald Trump Stock Impact Guide
-
Major Pharma Got a Major Win Last Night - BMO
-
Abbvie (ABBV) PTAB Decision Incrementally Positive, But Does Not Change Cautious Thesis - BMO
-
Inflectra's U.S. Launch Incrementally Positive for Pfizer (PFE), Negative for AbbVie (ABBV) - BMO
-
Streetinsider.com's Hot Lunchtime Reads 7/29: (WDC) (EPIQ) (ABBV) (ININ)
-
BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain
-
UPDATE: BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
BMO Capital Weighs in on Abbvie (ABBV) Amid IPR Decision
-
BMO Capital Positive on Abbvie (ABBV) Humira Win Versus Amgen (AMGN)
-
Streetinsider.com's Hot Lunchtime Reads 4/23: (GILD) (FB) (ABBV) (HLF)
-
Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says
-
Pharmacyclics (PCYC) Imbruvica CLL Update a Positive for Suitor Abbvie (ABBV) - BMO Capital
-
Notable Analyst Rating Changes 4/13: (NFLX) (ABBV) (UNH) Upgraded; (ANR) (PDS) (OMC) Downgraded
-
BMO Capital Upgrades Abbvie (ABBV) to Outperform
-
Positive Read-Through for Gilead Sciences (GILD) from ABBV/PCYC Deal
-
AbbVie's (ABBV) Pharmacyclics (PCYC) Deal Expensive, Done Out of Weakness - BMO Capital
-
Notable Analyst Rating Changes 2/9: (MOS) (PFE) (AMC) Upgraded; (CENX) (ANF) (RF) Downgraded
-
Abbvie (ABBV) PT Cut to $60 at BMO Capital as Cautious Thesis Materializing Faster
-
Streetinsider.com's Hot Lunchtime Reads 12/22: (GILD) (CUBA) (VHC) (ACHN)
-
Buy Gilead Sciences (GILD) on Weakness, BMO Capital Says; PT Dropped $20 on News
-
AbbVie's (ABBV) VIEKIRA PAK Seen as Limited Threat to Gilead's (GILD) HCV Dominance, BMO Capital Says
-
Notable Analyst Rating Changes 11/14: (RTN) (ESRT) (GERN) Upgraded; ((TJX) (LULU) (WMT) Downgraded
-
Notable Analyst Rating Changes 11/7: (CA) (GNC) (SPLK) Upgraded; (OXY) (ABBV) (SLXP) Downgraded
-
UPDATE: BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Notable Analyst Rating Changes 05/07: (JCP) (ABBY) (FE) Upgraded; (WFM) (GNC) (GRPN) Downgraded
-
Notable Analyst Rating Changes 12-19: (ELY) (FRX) (OMC) Upgraded; (SMTC) (F) (ABBV) Downgraded
-
Notable Analyst Rating Changes 12/03: (ABBV) (AAPL) (FRX) Upgraded; (PFE) (DIS) (AT) Downgraded
-
BMO Capital Upgrades Abbvie (ABBV) to Outperform
-
BMO Capital Downgrades Abbvie (ABBV) to Market Perform
-
Notable Analyst Rating Changes 01/02: (WAG) (X) (MAR) Upgraded; (SKUL) (LNKD) (KSS) Downgraded
-
BMO Capital Starts Abbvie (ABBV) at Outperform